Related Experiment Videos
FEIBA: mode of action.
P L Turecek1, K Váradi, H Gritsch
1Baxter BioScience, Vienna, Austria. peter_turecek@baxter.com
Haemophilia : the Official Journal of the World Federation of Hemophilia
|September 24, 2004
Summary
FEIBA, a treatment for hemophilia patients with inhibitors, works by enhancing thrombin generation. Key components like Factor Xa and prothrombin are crucial for its effectiveness in controlling bleeding.
Area of Science:
- Biochemistry
- Haematology
Background:
- FEIBA (factor eight inhibitor bypassing activity) has over 30 years of use in managing bleeding in hemophilic patients with inhibitors.
- These patients have developed antibodies against Factor VIII or Factor IX, necessitating alternative treatments.
Purpose of the Study:
- To elucidate the biochemical mechanisms underlying FEIBA's efficacy.
- To identify the key components and target sites responsible for FEIBA's hemostatic activity.
Main Methods:
- Biochemical analysis of FEIBA composition.
- In vitro and in vivo studies to assess the role of specific factors in thrombin generation.
- Investigation of the prothrombinase complex as a target.
Main Results:
- FEIBA contains prothrombin complex factors (prothrombin, FVII, FIX, FX) primarily as proenzymes, with notable amounts of FVIIa.
- Factor Xa and prothrombin were identified as critical components for FEIBA's activity.
- The prothrombinase complex was confirmed as a major target site for FEIBA.
Conclusions:
- FEIBA facilitates hemostasis by inducing and enabling thrombin generation.
- FXa and prothrombin are key activators within the FEIBA complex, crucial for its therapeutic effect.
- Other prothrombin complex proteins in FEIBA may also contribute to hemostasis in inhibitor patients.